Xuan Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xuan Hong has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Yingxu Zhou
Department of Medical Oncology
3 shared publicationsHongxue Meng
2 shared publicationsHung-Chih Chang
2 shared publicationsLan Huang
Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin China
2 shared publicationsMeng Wang
Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin China
2 shared publicationsYang Yang
2 shared publications
Latest Publications
- Open Access
- 30 May 2026
- Published by Elsevier in SSRN Electronic Journal
Single-Nucleus RNA Sequencing Reveals Stage-Specific Tumor Microenvironment Remodeling in TKI–Resistant EGFR-Mutant Lung Adenocarcinoma
Although EGFR tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with EGFR-mutant lung adenocarcinoma, most individuals harbor residual disease (RD) after treatment that inevitably leads to tumor progression due to acquired resistance. To elucidate the cellular dynamics driving therapy resistance, we utilized FFPE-compatible single-nucleus RNA sequencing (snRNA-seq) paired with multiplexed immunohistochemistry (mIHC) for spatial analysis. This approach allows us to map the cellular niches across the treatment trajectory from treatment-naive to RD and progressive disease (PD) stages. Our analysis revealed that beyond the survival of known TOP2A+/AURKA+ proliferative subclones, EGFR inhibition drives a specific subset of tumor cells to adopt a plastic, alveolar type II-like progenitor state that is maintained across all treatment stages, suggesting a novel adaptive mechanism for drug resistance. Crucially, we identified RD not as a dormant phase, but as a period of active tissue remodeling that serves as the structural foundation for resistance. This phase is driven by CTHRC1+ cancer-associated fibroblasts (CAFs) that produce extensive extracellular matrix, forming a physical barrier that shields tumor cells from immune infiltration. Spatial analysis confirmed that these fibroblasts and myeloid cells construct a protective environment that excludes cytotoxic T cells during RD. By redefining RD as an active stage where fibroblast-generated barriers shield cancer cells from immune attack, our findings identify this stromal remodeling as a critical therapeutic window. Disrupting this fibroblast-mediated shielding during RD could restore T-cell infiltration and cytotoxic activity, potentially eradicating residual tumor cells and preventing the evolution of clinical resistance.
- 30 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSingle-Nucleus RNA Sequencing Reveals Stage-Specific Tumor Microenvironment Remodeling in TKI–Resistant EGFR-Mutant Lung Adenocarcinoma
Although EGFR tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with EGFR-mutant lung adenocarcinoma, most individuals harbor residual disease (RD) after treatment that inevitably leads to tumor progression due to acquired resistance. To elucidate the cellular dynamics driving therapy resistance, we utilized FFPE-compatible single-nucleus RNA sequencing (snRNA-seq) paired with multiplexed immunohistochemistry (mIHC) for spatial analysis. This approach allows us to map the cellular niches across the treatment trajectory from treatment-naive to RD and progressive disease (PD) stages. Our analysis revealed that beyond the survival of known TOP2A+/AURKA+ proliferative subclones, EGFR inhibition drives a specific subset of tumor cells to adopt a plastic, alveolar type II-like progenitor state that is maintained across all treatment stages, suggesting a novel adaptive mechanism for drug resistance. Crucially, we identified RD not as a dormant phase, but as a period of active tissue remodeling that serves as the structural foundation for resistance. This phase is driven by CTHRC1+ cancer-associated fibroblasts (CAFs) that produce extensive extracellular matrix, forming a physical barrier that shields tumor cells from immune infiltration. Spatial analysis confirmed that these fibroblasts and myeloid cells construct a protective environment that excludes cytotoxic T cells during RD. By redefining RD as an active stage where fibroblast-generated barriers shield cancer cells from immune attack, our findings identify this stromal remodeling as a critical therapeutic window. Disrupting this fibroblast-mediated shielding during RD could restore T-cell infiltration and cytotoxic activity, potentially eradicating residual tumor cells and preventing the evolution of clinical resistance.
- Open Access
- 11 May 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (6) , 104814
Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
- 11 May 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (6) , 104814
Open AccessDiarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
- Open Access
- 1 January 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 4183326
Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
Background. Small cell lung cancer (SCLC) is an aggressive malignancy. Surgical resection is currently only recommended for clinical stage I patients who have been carefully staged. The clinical outcomes of patients with resected SCLCs vary because the disease is highly heterogeneous, suggesting that selected patients could be considered for surgical resection depending on their clinical and/or molecular characteristics. Methods. We collected data on a retrospective cohort of 119 limited‐stage SCLC patients who underwent lobectomy with mediastinal lymph node dissection from March 2013 to March 2020 at Harbin Medical University Cancer Hospital. Correlations were derived using Fisher’s exact test. Models of 2‐year and 3‐year survival were evaluated by deriving the area under receiver operating characteristic curves. Kaplan–Meier and Cox regression analyses were used to evaluate significant differences between the survival curves and hazard ratios. Results. The median disease‐free survival (DFS) was 35.9 months (range 0.9–105.3 months), and the median overall survival (OS) was 45.2 months (range 4.8–105.3 months). Univariate analysis showed that TNM stage was significantly correlated with DFS and OS. The 2‐year disease‐free rates of patients with stage I, II, and III disease were 76.4%, 50.5%, and 36.1%, respectively, and the 3‐year OS rates were 75.9%, 57.7%, and 34.4%, respectively. In pN + patients, multiple (or multiple‐station) lymph node involvement significantly increased recurrence and reduced survival compared with patients with single or single‐station metastases. Patients with peripheral SCLCs evidenced significantly better DFS and OS than did patients with central tumors. Multivariate analysis showed that TNM stage and tumor location were independently prognostic in Chinese patients with resected limited‐stage SCLC. A combination of TNM stage and tumor location was helpful for prognosis. Conclusions. TNM stage and tumor location were independently prognostic in Chinese patients with resected SCLCs. Patient stratification by tumor location should inform the therapeutic strategy. The role of surgical resection for limited‐stage SCLC patients must be reevaluated, as this may be appropriate for some patients.
- 1 January 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 4183326
Open AccessPeripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
Background. Small cell lung cancer (SCLC) is an aggressive malignancy. Surgical resection is currently only recommended for clinical stage I patients who have been carefully staged. The clinical outcomes of patients with resected SCLCs vary because the disease is highly heterogeneous, suggesting that selected patients could be considered for surgical resection depending on their clinical and/or molecular characteristics. Methods. We collected data on a retrospective cohort of 119 limited‐stage SCLC patients who underwent lobectomy with mediastinal lymph node dissection from March 2013 to March 2020 at Harbin Medical University Cancer Hospital. Correlations were derived using Fisher’s exact test. Models of 2‐year and 3‐year survival were evaluated by deriving the area under receiver operating characteristic curves. Kaplan–Meier and Cox regression analyses were used to evaluate significant differences between the survival curves and hazard ratios. Results. The median disease‐free survival (DFS) was 35.9 months (range 0.9–105.3 months), and the median overall survival (OS) was 45.2 months (range 4.8–105.3 months). Univariate analysis showed that TNM stage was significantly correlated with DFS and OS. The 2‐year disease‐free rates of patients with stage I, II, and III disease were 76.4%, 50.5%, and 36.1%, respectively, and the 3‐year OS rates were 75.9%, 57.7%, and 34.4%, respectively. In pN + patients, multiple (or multiple‐station) lymph node involvement significantly increased recurrence and reduced survival compared with patients with single or single‐station metastases. Patients with peripheral SCLCs evidenced significantly better DFS and OS than did patients with central tumors. Multivariate analysis showed that TNM stage and tumor location were independently prognostic in Chinese patients with resected limited‐stage SCLC. A combination of TNM stage and tumor location was helpful for prognosis. Conclusions. TNM stage and tumor location were independently prognostic in Chinese patients with resected SCLCs. Patient stratification by tumor location should inform the therapeutic strategy. The role of surgical resection for limited‐stage SCLC patients must be reevaluated, as this may be appropriate for some patients.
- 15 September 2021
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 75 (12) , e14877
Clinical outcomes of patients taking first‐generation EGFR‐TKIs may predict the benefits afforded by osimertinib in EGFR T790M‐mutant NSCLC patients
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used to treat patients with EGFR-mutated non-small cell lung cancers (NSCLCs). The association between the clinical outcomes of patients on first-line EGFR-TKIs and the efficacy of osimertinib as second-line treatment has not been previously assessed. This is our topic here. Patients and methods We retrospectively analyzed 67 patients with EGFR mutations on osimertinib after treatment with first-generation EGFR-TKIs. We evaluated patient characteristics, the EGFR T790M allele frequency in plasma samples, and clinical outcomes. Results When osimertinib was given as second-line treatment, the median progression-free survival (PFS) was 6.0 months, and the response rate and disease control rate were 32.8% and 91.0%, respectively. Correlation analysis showed that the female sex and isolated (not multiple) progression on first-line EGFR-TKIs were correlated with a superior response to osimertinib. Kaplan-Meier analysis showed that patients exhibiting a partial response, isolated progression, and longer PFS on first-line EGFR-TKIs experienced prolonged PFS on osimertinib. Univariate analysis indicated that the treatment response, PFS, and progression when on first-line EGFR-TKIs affected the PFS on osimertinib. Multivariate analysis showed that progression when on first-line EGFR-TKIs was independently prognostic of a response to osimertinib. The median PFS of patients with isolated progressive disease PD alone who were receiving brain radiotherapy was significantly longer than that of patients with isolated progressive disease alone who did not receive brain radiotherapy as well as patients exhibiting multiple progression. A low frequency of the EGFR T790M allele in plasma tended to predict an inferior efficacy of osimertinib and shorter PFS. Conclusion We found that patients who benefited from first-line EGFR-TKIs may experience prolonged PFS and a higher response rate when subsequently given osimertinib. A low plasma frequency of the EGFR T790M allele may predict poor osimertinib efficacy and shorter PFS.
- 15 September 2021
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 75 (12) , e14877
Clinical outcomes of patients taking first‐generation EGFR‐TKIs may predict the benefits afforded by osimertinib in EGFR T790M‐mutant NSCLC patients
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used to treat patients with EGFR-mutated non-small cell lung cancers (NSCLCs). The association between the clinical outcomes of patients on first-line EGFR-TKIs and the efficacy of osimertinib as second-line treatment has not been previously assessed. This is our topic here. Patients and methods We retrospectively analyzed 67 patients with EGFR mutations on osimertinib after treatment with first-generation EGFR-TKIs. We evaluated patient characteristics, the EGFR T790M allele frequency in plasma samples, and clinical outcomes. Results When osimertinib was given as second-line treatment, the median progression-free survival (PFS) was 6.0 months, and the response rate and disease control rate were 32.8% and 91.0%, respectively. Correlation analysis showed that the female sex and isolated (not multiple) progression on first-line EGFR-TKIs were correlated with a superior response to osimertinib. Kaplan-Meier analysis showed that patients exhibiting a partial response, isolated progression, and longer PFS on first-line EGFR-TKIs experienced prolonged PFS on osimertinib. Univariate analysis indicated that the treatment response, PFS, and progression when on first-line EGFR-TKIs affected the PFS on osimertinib. Multivariate analysis showed that progression when on first-line EGFR-TKIs was independently prognostic of a response to osimertinib. The median PFS of patients with isolated progressive disease PD alone who were receiving brain radiotherapy was significantly longer than that of patients with isolated progressive disease alone who did not receive brain radiotherapy as well as patients exhibiting multiple progression. A low frequency of the EGFR T790M allele in plasma tended to predict an inferior efficacy of osimertinib and shorter PFS. Conclusion We found that patients who benefited from first-line EGFR-TKIs may experience prolonged PFS and a higher response rate when subsequently given osimertinib. A low plasma frequency of the EGFR T790M allele may predict poor osimertinib efficacy and shorter PFS.
- Open Access
- 1 January 2020
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (24) , 7137-7145
Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer
Considering the existing indicators are not sufficient to predict the patient's response to immune checkpoint inhibitors (ICIs), we conducted this study to evaluate the efficacy and safety of ICIs in advanced non-small cell lung cancer (NSCLC) patients, and to determine prognostic factors of ICIs. In this study, 61 patients diagnosed with advanced NSCLC who underwent ICIs were recruited. The univariate analysis revealed the number of metastatic sites, immune-related adverse events (irAEs) (≥ G2) and best response were significantly associated with both progression-free survival (PFS) and overall survival (OS). Peripheral blood biomarkers, including post-treatment neutrophil-to-lymphocyte ratio (NLR) and CEA levels were also associated with PFS, but not OS. The irAEs (≥ G2), best response and age were confirmed as independent predictors of a prolonged survival by multivariate analysis. The development of irAEs ≥ G2 correlated with a survival benefit in patients with advanced NSCLC (median PFS: 7.1 months vs. 4.6 months, P = 0.013). Thus, we concluded that identifying predictors of benefit from ICIs treatment will help to further extend patient survival in advanced NSCLC.
- 1 January 2020
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (24) , 7137-7145
Open AccessClinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer
Considering the existing indicators are not sufficient to predict the patient's response to immune checkpoint inhibitors (ICIs), we conducted this study to evaluate the efficacy and safety of ICIs in advanced non-small cell lung cancer (NSCLC) patients, and to determine prognostic factors of ICIs. In this study, 61 patients diagnosed with advanced NSCLC who underwent ICIs were recruited. The univariate analysis revealed the number of metastatic sites, immune-related adverse events (irAEs) (≥ G2) and best response were significantly associated with both progression-free survival (PFS) and overall survival (OS). Peripheral blood biomarkers, including post-treatment neutrophil-to-lymphocyte ratio (NLR) and CEA levels were also associated with PFS, but not OS. The irAEs (≥ G2), best response and age were confirmed as independent predictors of a prolonged survival by multivariate analysis. The development of irAEs ≥ G2 correlated with a survival benefit in patients with advanced NSCLC (median PFS: 7.1 months vs. 4.6 months, P = 0.013). Thus, we concluded that identifying predictors of benefit from ICIs treatment will help to further extend patient survival in advanced NSCLC.
- Open Access
- 7 June 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 16 (2) , 879-885
miR‑6852 serves as a prognostic biomarker in colorectal cancer and inhibits tumor growth and metastasis by targeting TCF7
MicroRNAs (miRs) are have been demonstrated to serve important functions in the genesis of human cancer, including colorectal cancer (CRC). The role of miR‑6852 in CRC remains unknown. In this study, it was demonstrated that miR‑6852 was underexpressed in CRC tissues compared with adjacent normal tissues. Moreover, the expression of miR‑6852 was negatively correlated with CRC metastasis, whereas positively correlated with patient prognosis. It was revealed that the overexpression of miR‑6852 significantly inhibited the proliferation and invasion of CRC cells. miR‑6852 overexpression reduced CRC cells in the S phase. TCF7 was identified to be a direct target of miR‑6852 in CRC cells. Overexpression of miR‑6852 significantly inhibited the mRNA and protein levels of TCF7 in CRC cells. Furthermore, TCF7 was highly expressed in CRC tissues and cell lines. TCF7 expression was negatively correlated with miR‑6852 levels in CRC tissues. Finally, knockdown of TCF7 significantly suppressed the proliferation and invasion of CRC cells. Taken together, the results of the present study indicated that miR‑6852 serves as a tumor suppressor in CRC through targeting TCF7.
- 7 June 2018
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 16 (2) , 879-885
Open AccessmiR‑6852 serves as a prognostic biomarker in colorectal cancer and inhibits tumor growth and metastasis by targeting TCF7
MicroRNAs (miRs) are have been demonstrated to serve important functions in the genesis of human cancer, including colorectal cancer (CRC). The role of miR‑6852 in CRC remains unknown. In this study, it was demonstrated that miR‑6852 was underexpressed in CRC tissues compared with adjacent normal tissues. Moreover, the expression of miR‑6852 was negatively correlated with CRC metastasis, whereas positively correlated with patient prognosis. It was revealed that the overexpression of miR‑6852 significantly inhibited the proliferation and invasion of CRC cells. miR‑6852 overexpression reduced CRC cells in the S phase. TCF7 was identified to be a direct target of miR‑6852 in CRC cells. Overexpression of miR‑6852 significantly inhibited the mRNA and protein levels of TCF7 in CRC cells. Furthermore, TCF7 was highly expressed in CRC tissues and cell lines. TCF7 expression was negatively correlated with miR‑6852 levels in CRC tissues. Finally, knockdown of TCF7 significantly suppressed the proliferation and invasion of CRC cells. Taken together, the results of the present study indicated that miR‑6852 serves as a tumor suppressor in CRC through targeting TCF7.
- 16 August 2013
- Vol. 29 (2) , 273-8
Somatic mutation of KIT is rare in small cell lung cancer patients from Northeast China.
Studies have confirmed that protein overexpression or mutations of KIT are involved in growth and development of a variety of cancers. however, little is known about data of gene mutation and protein expression in small cell lung cancer (SCLC) patients from northeast China.The aim of study is to investigate gene mutation and protein expression in such patients with small cell lung cancer (SCLC) and analyse their clinical significance.The expression of c-Kit protein was analyzed by immunohistochemistry in 77 SCLC samples and 22 normal lung samples. KIT mutations were screened in exons 9, 11, 13, 14, 17 and 18 by DNA direct sequencing.The study showed that positive staining for c-Kit was observed in 28 of 77 SCLC patients . There was no correlations between expression of c-Kit and sex, ages, smoking status, stage. only 1 case was found to have known T801I mutation in exon 17. The median survival (13.9 months) of cases with c-Kit-positive was shorter than that (19.9 months) of cases with c-Kit-negative. The finding revealed that stages was identified as an independent predictive factor for SCLC patients.Our finding reveals that somatic mutation of KIT is rare in SCLC patients from the northeast China and there is no enough evidence comfirming KIT inhibitors for treatment in SCLC.
- 16 August 2013
- Vol. 29 (2) , 273-8
Somatic mutation of KIT is rare in small cell lung cancer patients from Northeast China.
Studies have confirmed that protein overexpression or mutations of KIT are involved in growth and development of a variety of cancers. however, little is known about data of gene mutation and protein expression in small cell lung cancer (SCLC) patients from northeast China.The aim of study is to investigate gene mutation and protein expression in such patients with small cell lung cancer (SCLC) and analyse their clinical significance.The expression of c-Kit protein was analyzed by immunohistochemistry in 77 SCLC samples and 22 normal lung samples. KIT mutations were screened in exons 9, 11, 13, 14, 17 and 18 by DNA direct sequencing.The study showed that positive staining for c-Kit was observed in 28 of 77 SCLC patients . There was no correlations between expression of c-Kit and sex, ages, smoking status, stage. only 1 case was found to have known T801I mutation in exon 17. The median survival (13.9 months) of cases with c-Kit-positive was shorter than that (19.9 months) of cases with c-Kit-negative. The finding revealed that stages was identified as an independent predictive factor for SCLC patients.Our finding reveals that somatic mutation of KIT is rare in SCLC patients from the northeast China and there is no enough evidence comfirming KIT inhibitors for treatment in SCLC.